Close Menu

NEW YORK — The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed at Columbia University.

The Triplex CII-SARS-CoV-2 rRT-PCR test is designed to detect the SARS-CoV-2 nucleocapsid gene in nasopharyngeal, oropharyngeal, nasal, and midturbinate nasal swab samples. It uses the BioMérieux easyMAG automated extraction platform using the NucliSENS easyMAG extraction kit and Thermo Fisher Scientific's Applied Biosystem 7500 Fast Dx Real-Time PCR Instrument with software version 2.3.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.